Eisai and Biogen’s Alzheimer’s drug Leqembi has received a thumbs down from the European Medicines Agency’s expert committee, which raised concerns about safety and limited efficacy.
The news is a major setback for the two companies, as the EU is expected to be the second biggest market for the drug after the US
If Leqembi were approved, it would become the EU’s first disease-modifying drug for Alzheimer’s and could pave